Aktien Sensor

Bayer’s stock price has experienced fluctuations, but remains relatively stable, while its pharmaceutical division shows promise with the approval of Finerenon in over 90 countries.

Bayer’s stock price has surged 1.5% as the company prepares to sell a 4.5 million euro art collection, potentially generating significant revenue for future growth and innovation.

Bayer’s heart medication Acoramidis has received EU approval, potentially boosting the company’s revenue and market share, but its success is uncertain and may not be enough to revive its dwindling fortunes.